One change, many consequences:

The packaging of a medicinal product or dietary supplement performs a series of crucial functions, the most important of which is protecting the product. It safeguards it against environmental factors such as moisture, light, or mechanical damage that can negatively affect its quality, stability, and efficacy. Consequently, packaging has a direct impact on patient safety. It is also responsible for proper transport, storage, and unambiguous identification of the product throughout the entire supply chain.

These are fundamental truths that are not up for debate in the pharmaceutical industry. In practice, however, this means something much more critical: packaging is not just an add-on to the product, but an integral part of it. Any change made to it, even a seemingly minor one, can trigger a chain of quality, operational, and regulatory consequences. This raises a key question: do we really treat every packaging and leaflet change with the same diligence as a change to the medicinal product itself?

Why a packaging change is never “just a graphic update”

Today’s pharmaceutical market is highly dynamic. Updates driven by regulatory requirements (such as serialization and traceability), variations in registration dossiers, product portfolio expansions, marketing campaigns, and cost pressures mean that packaging modifications are occurring more frequently than ever.

In many cases, these changes seem minor—a text correction in a Patient Information Leaflet (PIL), a carton layout adjustment, or an update to the material of the box or leaflet. However, each of these modifications carries potential quality risks and requires thorough preparation. It is crucial to understand that packaging is responsible not only for conveying information but also for the safe use of the product, its traceability, and compliance with regulatory standards. Therefore, any modification should be analyzed with the same level of care as a change to the drug formulation itself.

What can actually change? Types of changes in pharmaceutical packaging

For products already on the market, packaging changes are a natural part of their lifecycle. They can stem from regulatory mandates, business needs, or process optimizations. In practice, they can affect various areas of the packaging and vary significantly in their impact on production, regulatory compliance, and product safety.

We can categorize changes in pharmaceutical and dietary supplement packaging into several main areas, each carrying a different risk profile and requiring a distinct approach:

Graphic and Textual Changes: These are among the most common. They include PIL updates, carton artwork modifications, or the introduction of new language versions. Although they may seem purely visual, they are actually one of the most sensitive areas. They demand full compliance with the registration dossier and extreme attention to substantive accuracy. In this case, design is merely a starting point—the priority is compliance with current regulations and the safety of the information provided to the patient.

Structural Changes: These relate to the construction of the packaging, including the die-cut template, the closure system, or the integration of tamper-evident features. They directly affect the packaging’s functionality and its compatibility with packaging lines. Their impact is felt most acutely during production, where even minor modifications can disrupt line efficiency and packaging stability.

Material Changes: These involve changing the type of cardboard, its grammage, the supplier, or the inks and varnishes used. Increasingly, these changes are driven by environmental requirements and regulations such as the Packaging and Packaging Waste Regulation (PPWR). New regulations mandate designing packaging with recycling in mind and transitioning toward a circular economy. For pharma, this means reducing excess packaging volume and increasing the use of recycled materials—a unique challenge. Any material change, especially in primary packaging, requires not only safety testing but often also updates to the registration dossier and marketing authorization variations. Additionally, requirements under Directive 2001/83/EC must be met, which dictate the mandatory information on the packaging, directly influencing its size and layout.

Process Changes: These include switching printing technologies or changing the packaging supplier. In practice, these are among the most complex and demanding changes because they impact the entire manufacturing process. They require proper preparation, supplier qualification, audits, and production trials. This area demands the most comprehensive approach, blending quality and operational perspectives.

The nature of the change dictates both the risk level and the scope of actions needed for a safe rollout. Consequently, the early involvement of quality, regulatory, and technical teams is paramount.

Main areas of quality risk: what to remember and how to prepare

Packaging changes can impact product safety as well as production, logistics, and registration processes. Therefore, before implementation, it is vital to identify key risk areas and define control measures.

Risk of substantive errors

One of the most critical areas is content accuracy. Outdated information in a leaflet, dosage errors, or discrepancies between the carton and the leaflet can directly threaten patient health and life. Every content update must undergo multi-stage verification—both by subject-matter experts and automated inspection systems.

Special attention must be paid to Braille, which is mandatory for medicinal products in the European Union and the UK. Its correctness and legibility directly affect the safety and independence of visually impaired patients. Requirements here are governed by the ISO 17351 standard, which defines rules for embossing, spacing, and quality control. It is vital to integrate Braille at the design stage; delaying this decision often leads to redesigns and launch delays. Factors affecting Braille quality include:

• Cardboard thickness and properties
• Quality and precision of embossing tools
• Applied surface coatings
• Proper placement within the packaging structure (away from folds and cuts)

Improperly executed Braille can delay product release. When making changes—especially when changing suppliers—running test batches and performing strict quality checks is highly recommended. While these are highly technical details for the print shop to manage, manufacturers must understand what to look out for.

Regulatory compliance risk

The pharmaceutical industry operates under a strict regulatory regime, meaning any packaging change must comply with the approved dossier. This applies to both text and the graphic layout of the artwork, which are subject to formal approval. Market supervision is conducted by bodies such as the European Medicines Agency (EMA), the Chief Pharmaceutical Inspectorate (GIF) in Poland, and the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL).

In Poland, packaging changes require a notification procedure under pharmaceutical law. The packaging must contain specific mandatory information (e.g., product name, composition, pharmaceutical form, route of administration, expiry date, batch number, and marketing authorization holder details) alongside the product name in Braille. Any modification to these elements requires formal evaluation and approval.

Functional packaging risk

Structural or material changes can alter how packaging behaves during packing and distribution. Issues like inadequate cardboard stiffness, suboptimal design, or closure difficulties can lead to downtime on production lines, increased material waste, and delivery delays. Flaws in a design often first show up on the packaging line. This is why conducting functional tests and matching the packaging to real production environments is so critical.

Traceability and serialization risk

Another key area is the accuracy of variable data and identification systems. Serialization, required by the Falsified Medicines Directive (FMD), mandates a unique identifier for each individual product unit. The 2D DataMatrix code must contain the batch number, expiry date, product code, and a unique serial number. Additionally, the packaging must feature a tamper-evident seal.

The print quality of this data is vital—an unreadable code can prevent a product from being released or distributed. Designing dedicated print fields for variable data and choosing the right materials and printing technologies is essential. Even minor details, like varnish coverage in the print area, can ruin code legibility.

Visual and reputational risk

Though often deemed less critical, visual risks carry heavy operational and brand consequences. Color discrepancies between batches, poor print quality, or hard-to-read text can damage brand perception and, in extreme cases, cause patient confusion. Maintaining visual consistency is essential for established products. This requires sharing precise color standards and reference samples, especially during a supplier transition. For new designs, involving the print partner early in the concept stage helps avoid structures that are difficult or impossible to manufacture.

Quality in pharmaceutical packaging production is not just about ticking compliance boxes. It involves design details, technical parameters, and practical expertise. In this industry, seemingly small decisions can directly impact patient safety and regulatory compliance. Every change—including switching suppliers—must be treated as a process requiring a holistic approach: from risk assessment and testing to tight collaboration between quality and technical teams.

When is the risk of errors highest? A practical perspective

Experience shows that errors in packaging or leaflet changes are rarely caused by a single oversight. Most often, they occur at the interfaces between phases, systems, and teams—where responsibility is fragmented and communication is unaligned. Implementing a new packaging design or modifying an existing one is a multi-step process involving marketing, regulatory affairs, production, and external suppliers. Each additional touchpoint increases the risk of data inconsistency or missed details.

The most critical moments include:

1. The preparation of graphic files and their prepress adaptation.
2. The transfer of data and artwork between systems and teams.
3. The approval process—especially in environments with multiple versions and no centralized digital asset management.
4. The first production run following a change.
5. A transition to a new packaging material supplier.

These points are where inconsistencies, version control errors, or incomplete design implementations most frequently occur.

The process typically starts in a graphic design studio with updates to content, layout, or artwork elements. Once modified, the design goes to the client for verification and, upon approval, to the print shop for prepress. At this stage, the design must be verified against technical requirements: choosing the right substrate, verifying the die-cut line, and preparing files for print.

If a change is purely graphical, the process can run relatively smoothly. In reality, however, companies often face overlapping modifications—such as simultaneous changes to packaging structure, material, and supplier. Each added layer increases project complexity, extends lead times, and raises the risk profile.

Supplier transitions coupled with packaging changes are particularly demanding. In these scenarios, you must replicate the existing quality standard while managing new qualifications, tests, and technical alignments. Without thorough preparation, this leads to delays, production bottlenecks, or quality defects. For projects combining structural, material, and supplier changes, meticulous scheduling and clear milestones are vital.

How to minimize risk? Best practices

Effective risk mitigation requires a systemic, process-oriented approach. This is the only way to minimize—and often completely eliminate—potential errors. Change Control plays a key role here, and should include formal procedures and a thorough risk assessment covering all stages of the packaging lifecycle.

1. Establish an Adequate Time Horizon

In business, time-to-market often dictates competitive advantage. Consider a common scenario: the formulation is ready, documentation is finalized, and production is starting—but a packaging change was delayed. When this phase starts too late, time becomes a major bottleneck. Packaging is not just a “box”; it is a complex journey of conceptualization, design, material selection, color proofing, and manufacturing.

Rushing this process limits room for adjustments and often leads to compromises in aesthetics, functionality, or final quality. Manufacturing packaging—especially with finishes or custom structures—takes time. Tooling like die-cut plates, embossing dies, or specialty substrates are not always available off the shelf. Therefore, your product launch timeline must account for the full design and production cycle of the secondary packaging. It makes the first impression, so give it the time it deserves to be perfected.

2. Standardize and Control Artworks

Utilizing version-controlled artwork management systems eliminates the risk of using outdated files and ensures a transparent approval loop. Digitalization is playing a growing role here. Integrating ERP systems, implementing strict file version controls, maintaining structured approval flows, and securing data exchange drastically reduce errors and streamline client-printer collaboration.

Platform-based environments where projects, approvals, and order statuses are managed in a single space with real-time tracking are quickly becoming the industry standard. Furthermore, these systems should archive all historical data—production, logistics, technical specifications, and deliveries—according to client needs. The more organized and digital the print shop’s workflow, the lower the risk of errors during file transfer. This is a key capability to look for when selecting a partner.

3. Leverage Prepress and Proofing

The prepress department is your defense line; it is where many errors can be caught before printing plates are made. Color proofs (mockups) also play a vital role, allowing you to verify the final look before production. Partnering with a modern print shop that acts as a process consultant rather than just an order-taker significantly elevates project safety.

Modern print shops utilize automated tools at the initial file verification stage to flag elements needing correction. During the prepress and proofing stage, a professional print shop provides clear technical guidelines. Common file issues that slow down implementation include:

• Missing bleeds
• Incorrect ICC color profiles
• Errors in spot varnish/embossing masks
• Tiny typography

Physical packaging prototypes and sample prints allow you to verify colors, structure, and finishes before signing off on final production files.

The role of the printing house as a partner in managing packaging or leaflet changes

Collaboration between the manufacturer and the printing house is vital for process safety and quality. Clear communication, shared checklists, and digital artwork tools greatly reduce the room for error. It is equally important to involve the printing house early during the design phase of a change, rather than only during file finalization.

A modern pharmaceutical packaging printing house is far more than a manufacturer—it is an integral part of the supply chain, subject to strict quality audits. Hygiene standards in print shops producing pharma packaging and leaflets are also under increasing scrutiny. Production environment organization, cleanliness controls, and staff training are key metrics in quality audits. In practice, these requirements bring the operations of pharma printers closer to GMP (Good Manufacturing Practice) standards. Industry expertise, comprehensive quality control systems, full traceability, and technical support directly safeguard the entire process.

Advanced technology also plays an important role. Inline print inspection systems and cutting-edge machinery allow for continuous quality monitoring and minimize deviations during production. Camera systems, automatic defect detection, and real-time analysis monitor every step of the run, generating reports that meet strict audit requirements. This ensures errors are caught early, waste is reduced, and packaging remains fully compliant with specifications.

This proactive approach minimizes complaints and delays while driving continuous quality improvement based on process data. For pharmaceutical manufacturers, this offers peace of mind that their product will enter the market on time, in perfect condition, and in full compliance.

What makes a good print partner?

A high-quality print shop is defined by more than its machinery and price list. Look for a team that:

• Understands the specific demands of the pharmaceutical and cosmetics markets.
• Has proven experience working with highly regulated brands.
• Features a modern machinery fleet that guarantees high quality and production flexibility.
• Uses inline print inspection systems to catch errors and accelerate runs.
• Invests in digital platforms for order management, approvals, and communication.

When selecting a partner, look past simple capacity. Evaluate their pharmaceutical expertise, quality standards, inspection systems, and technical support. Engaging your printer early brings the greatest rewards. Transparent guidelines, joint planning, and clear milestones set during the brief stage dramatically reduce the risk of errors, misunderstandings, and delays.

A strong print partner does not just print—they advise. They help select the right materials, identify risks, and recommend cost-effective technical solutions. Having such a partner on your side directly improves the quality, safety, and predictability of your entire supply chain.

What to verify before implementing a packaging change?

In the pharmaceutical sector, packaging is not a mere marketing tool or information carrier. It is an integral component of the medicinal product and a pillar of patient safety. Therefore, every change—no matter how minor it appears—must be treated as a quality process requiring risk assessment, planning, and strict control.

Ultimately, success is not determined by the change itself, but by how it is executed. The intersection of regulatory affairs, technology, quality, and production is where errors most often occur, potentially disrupting product safety, supply continuity, and market compliance.

As regulatory demands and manufacturing complexities grow, the partnership between pharmaceutical producers and packaging suppliers becomes paramount. Technical expertise, quality standards, digital workflows, and GMP alignment are no longer optional extras—they are requirements for safe change management. In pharma, there are no “small changes.” There are only changes that were thoroughly prepared—and those whose consequences are discovered too late.